| NCCN guidelines insights: hematopoietic growth factors, version 1.2020: featured updates to the NCCN guidelines PS Becker, EA Griffiths, LM Alwan, K Bachiashvili, A Brown, R Cool, ... Journal of the National Comprehensive Cancer Network 18 (1), 12-22, 2020 | 88 | 2020 |
| Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic EA Griffiths, LM Alwan, K Bachiashvili, A Brown, R Cool, P Curtin, ... Journal of the National Comprehensive Cancer Network 19 (13), 18-21, 2020 | 48 | 2020 |
| NCCN Guidelines® insights: hematopoietic growth factors, version 1.2022: featured updates to the NCCN guidelines EA Griffiths, V Roy, L Alwan, K Bachiashvili, J Baird, R Cool, S Dinner, ... Journal of the National Comprehensive Cancer Network 20 (5), 436-442, 2022 | 36 | 2022 |
| Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia S Arora, P Vachhani, K Bachiashvili, O Jamy Leukemia & Lymphoma 62 (9), 2292-2294, 2021 | 14 | 2021 |
| Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer J Anampa, T Haque, I Murakhovskaya, Y Wang, K Bachiashvili, ... haematologica 103 (3), e98, 2018 | 10 | 2018 |
| Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia S Arora, C Zainaldin, S Bathini, U Gupta, S Worth, K Bachiashvili, ... Leukemia Research 117, 106844, 2022 | 8 | 2022 |
| Relapsing fever caused by Borrelia lonestari after tick bite in Alabama, USA LJV Guillamet, GE Marx, W Benjamin, P Pappas, NAP Lieberman, ... Emerging Infectious Diseases 29 (2), 441, 2023 | 7 | 2023 |
| ASTX727-03: phase 1 study evaluating oral decitabine/cedazuridine (ASTX727) low-dose (LD) in lower-risk myelodysplastic syndromes (LR-MDS) patients G Garcia-Manero, K Bachiashvili, H Amin, E Traer, DA Pollyea, ... Blood 140 (Supplement 1), 1112-1114, 2022 | 5 | 2022 |
| Clinical ALK5 inhibitor, vactosertib, reverses TGFβ-1 stimulated Smad-2 driven ineffective hematopoiesis in MDS S Aluri, K Bachiashvili, A Budhathoki, TD Bhagat, GS Choudhary, ... Blood 134, 2990, 2019 | 4 | 2019 |
| Targeting the anterior superior iliac spine yields significantly longer bone marrow cores L Reed, S Attarian, G Pendurti, AP Singh, A Budhathoki, S Abi-Aad, ... Journal of Clinical Pathology 71 (2), 172-173, 2018 | 4 | 2018 |
| Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents C Zainaldin, S Arora, S Bathini, U Gupta, V Pandya, S Bae, S Worth, ... Leukemia & Lymphoma 63 (13), 3245-3248, 2022 | 3 | 2022 |
| Peripheral blood parameter abnormalities precede therapy‐related myeloid neoplasms after autologous transplantation for lymphoma K Bachiashvili, L Francisco, Y Chen, A Bosworth, SJ Forman, R Bhatia, ... Cancer 128 (7), 1392-1401, 2022 | 3 | 2022 |
| First report of novel heterozygous WRAP53 p. Ala522Glyfs* 8 mutation associated dyskeratosis congenita. T Magnusson, RC Godby, K Bachiashvili, O Jamy British Journal of Haematology 196 (4), 2022 | 3 | 2022 |
| Hematopoietic growth factors, version 1.2020: featured updates to the NCCN guidelines PS Becker, EA Griffiths, LM Alwan, K Bachiashvili, A Brown, R Cool, ... JNCCN Journal of the National Comprehensive Cancer Network 18 (1), 12-22, 2020 | 3 | 2020 |
| Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia. O Jamy, K Lin, S Worth, K Bachiashvili, S Rangaraju, P Vachhani, ... British Journal of Haematology 198 (3), 2022 | 2 | 2022 |
| Visualization of the bone marrow biopsy needle track S Attarian, L Reed, S Singh, A Shestopalov, AP Singh, A Budhathoki, ... American journal of hematology 93 (3), E60-E61, 2018 | 2 | 2018 |
| Impact of induction intensity and transplantation on outcomes of patients with complex karyotype and TP53-mutated acute myeloid leukemia O Jamy, K Diebold, K Davis, K Bachiashvili, S Rangaraju, P Vachhani, ... Bone Marrow Transplantation 58 (7), 823-825, 2023 | 1 | 2023 |
| Outcomes of 3-versus 5-day administration schedule of consolidation cytarabine in adults with acute myeloid leukemia (AML). K Diebold, K Bachiashvili, OH Jamy, P Vachhani, KN Godby, R Bhatia, ... Journal of Clinical Oncology 41 (16_suppl), 7014-7014, 2023 | 1 | 2023 |
| Safe and effective use of imatinib to treat Philadelphia chromosome positive acute lymphoblastic leukemia during pregnancy S Ashraf, J Wolfson, P Vachhani, S Rangaraju, K Bachiashvili, R Bhatia, ... Journal of adolescent and young adult oncology 11 (6), 617-620, 2022 | 1 | 2022 |
| A phase 1 study of NTX-301, an oral DNMT1 inhibitor, in patients with MDS and AML (trial in progress). P Vachhani, GSG Murthy, O Jamy, K Bachiashvili, S Rangaraju, T Cole, ... Journal of Clinical Oncology 40 (16_suppl), TPS7077-TPS7077, 2022 | 1 | 2022 |
